Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

Jefferies analyst Roger Song has maintained a Buy rating on CytomX Therapeutics (NASDAQ: CTMX) and increased the price target from $8 to $16. This adjustment reflects a positive outlook for the company's performance.